Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies

Lung cancer is the second most common cancer in the United States, and small cell lung cancer (SCLC) accounts for about 15% of all lung cancers. In SCLC, more than other malignancies, the standard of care is based on clinical demonstration of efficacy, and less on a mechanistic understanding of why...

Descripción completa

Detalles Bibliográficos
Autores principales: Liguori, Nicholas R., Lee, Young, Borges, William, Zhou, Lanlan, Azzoli, Christopher, El-Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438120/
https://www.ncbi.nlm.nih.gov/pubmed/34531756
http://dx.doi.org/10.3389/fphar.2021.747180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438120/
https://www.ncbi.nlm.nih.gov/pubmed/34531756
http://dx.doi.org/10.3389/fphar.2021.747180

Ejemplares similares